UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification Number) |
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including
area code: (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 7.01 Regulation FD Disclosure.
Medicus Sciences Acquisition Corp. (the “Company”) has approached Anteris Technologies Ltd (“Anteris”), a company listed on the Australian Securities Exchange (“ASX”), with a proposal to enter into discussions regarding a possible business combination transaction and to negotiate a non-binding letter of intent in contemplation of such a possible transaction. As of the date of this filing, there is no letter of intent in effect between the Company and Anteris and related discussions are ongoing. Nevertheless, Anteris made a determination that pursuant to applicable Australian securities laws, it was required to make a public announcement disclosing that it had been approached by the Company, which it did on February 8, 2022.
Sio Capital Management, LLC is both (i) the holder of a significant equity interest in the Company’s sponsor, Medicus Sciences Holdings LLC, and (ii) a significant direct and indirect holder of shares in Anteris. Pursuant to Australian securities laws, the Company has filed, or will simultaneously herewith file, a notice with the ASX in connection with these relationships. The Company is not a direct or beneficial owner of any shares or other securities of Anteris.
The information set forth below under this Item 7.01 is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as expressly set forth by specific reference in such filing.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| MEDICUS SCIENCES ACQUISITION CORP. | |||
| By: | /s/ Michael Castor | ||
| Name: | Michael Castor | ||
| Title: | Chief Executive Officer | ||
Dated: February 8, 2022